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Abstract
Background: To report our long-term results with postoperative intensity-modulated radiation therapy (IMRT) in
patients suffering from squamous-cell carcinoma (SCC) of the oral cavity or oropharynx.
Methods: Seventy five patients were retrospectively analyzed. Median age was 58 years and 84 % were male. 76 % of
the primaries were located in the oropharynx. Surgery resulted in negative margins (R0) in 64 % of the patients while
36 % suffered from positive margins (R1). Postoperative stages were as follows: stage1:4 %, stage2:9 %, stage3:17 %,
stage4a:69 % with positive nodes in 84 %. Perineural invasion (Pn+) and extracapsular extension (ECE) were present in
7 % and 29 %, respectively. All patients received IMRT using the step-and-shoot approach with a simultaneously
integrated boost (SIB) in 84 %. Concurrent systemic therapy was applied to 53 patients, mainly cisplatin weekly.
Results: Median follow-up was 55 months (5–150). 13 patients showed locoregional failures (4 isolated local, 4 isolated
neck, 5 combined) transferring into 5-year-LRC rates of 85 %. Number of positive lymph nodes (n > 2) and presence of
ECE were significantly associated with decreased LRC in univariate analysis, but only the number of nodes remained
significant in multivariate analysis. Overall treatment failures occurred in 20 patients (9 locoregional only, 7 distant only,
4 combined), transferring into 3-and 5-year-FFTF rates of 77 % and 75 %, respectively. The 3-and 5-year-OS rates were
80 % and 72 %, respectively. High clinical stage, high N stage, number of positive nodes (n > 2), ECE and Pn1 were
significantly associated with worse FFTF and OS in univariate analysis, but only number of nodes remained significant
for FFTF in multivariate analysis. Maximum acute toxicity was grade 3 in 64 % and grade 4 in 1 %, mainly hematological
or mucositis/dysphagia. Maximum late toxicity was grade 3 in 23 % of the patients, mainly long-term tube feeding
dependency.
Conclusion: Postoperative IMRT achieved excellent LRC and good OS with acceptable acute and low late toxicity rates.
The number of positive nodes (n > 2) was a strong prognostic factor for all endpoints in univariate and the
only significant factor for LRC and FFTF in multivariate analysis. Patients with feeding tubes due to postoperative
complications had an increased risk for long-term feeding tube dependency.
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Background
The main treatment modalities for head and neck cancer
are surgery and radiation therapy [1–5]. While very early
stages can be successfully treated with one of those mo-
dalities alone, surgical candidates with more advanced
stages usually require the combination of both [5] to
achieve satisfactory locoregional control. Further on,
enhancement of radiation therapy by simultaneous appli-
cation of chemotherapy has been shown to be advanta-
geous according to randomized trials in the presence of
several risk factors especially positive or close resection
margins and nodal involvement with extracapsular exten-
sion (ECE) [3, 4, 6]. However, in most of these trials
patients with different tumor locations have been included
and treated uniformly, although tumor localization might
influence treatment opportunities and outcome both
regarding oncological and functional endpoints [7, 8]. For
example, surgical opportunities in oral cavity and oropha-
ryngeal tumors can be limited with regard to radicality be-
cause of unacceptable functional deficits [9], which fueled
even the investigation of neoadjuvant chemoradiation
approaches specifically in those cases [10]. In fact several
authors reported different outcomes for oral cavity or oro-
pharyngeal tumors compared to other head and neck sites
[8, 11]. However, both surgical and radiation therapy tech-
niques have evolved in the last decades. While the surgical
approach has been improved for example by the widened
use of reconstructions with microvascular free flaps [9],
the introduction of intensity-modulated radiation therapy
(IMRT) represents a major progress in radiation therapy.
As shown by various dosimetric and clinical studies,
IMRT allows improved target coverage and reduced dose
to organs at risk at the same time which consequently
leads to less acute and late toxicities [12, 13]. Further on,
IMRT offers a simple solution to apply slightly accelerated
doses in areas of high risk [14–16] like the surgical cavity
without increasing the number of fractions (so-called sim-
ultaneously integrated boost concept, SIB). Taken to-
gether, little long-term data exists specifically addressing
the subgroup of patients with oral cavity or oropharyngeal
primaries treated with postoperative IMRT with or
without chemotherapy depending on the presence of
risk factors established in randomized trials using
conventional techniques. We therefore retrospectively
evaluated our patients treated in this setting with
regard to outcome, toxicity and possible prognostic fac-
tors to gain a more specific insight into the long-term




We retrospectively analyzed our patients with squamous
cell cancer of the oral cavity or the oropharynx who have
been treated with postoperative intensity-modulated
radiation therapy after gross complete resection at our
institution between 2000 and 2010. Oral cavity cancer
was defined as primary tumor located in the mucosal
surface of lip, floor of mouth, oral tongue, buccal mucosa,
lower and upper gingival, hard palate and retromolar
trigone, according to UICC6th definition. Oropharyngeal
cancer was defined as primary tumor located in the soft
palate, tonsil, base of tongue and lateral or posterior wall
of the pharynx between soft palate and hyoid according to
UICC6th definition. Patients with distant spread or locally
recurrent disease at presentation, gross residual disease
after resection, prior radiation therapy of the head and
neck region, induction chemotherapy or non-squamous
cell cancer histology were excluded. The remaining 75
patients formed the basis of the current analysis. Median
age was 58 years (35–85) and 84 % were male. 61 % of the
primaries were located in the oropharynx. Surgery
resulted in microscopically negative margins (R0) in 64 %
of the patients while 36 % suffered from positive margins
(R1). All patients received ipsilateral (45 %) or bilateral
neck dissections (55 %). Postoperative tumor stages
(UICC6th 2002) were distributed as follows: stage 1: 3 %,
stage 2:7 %, stage 3: 13 %, stage 4a: 52 % with positive
nodes in 84 % of the patients. Grading was G1 in 3 %, G2
in 57 % and G3 in 40 %. Perineural invasion (Pn+) was
present in 7 %, extracapsular extension (ECE) in 29 %. For
detailed patient characteristic see Table 1.
Work-up and surgery
Initial work-up prior to surgery included clinical and
laboratory examination, computed tomography (CT)
and/or magnetic resonance imaging (MRI) of the head
and neck, endoscopy with histological confirmation,
chest x-ray or CT and abdominal ultrasound or CT.
Surgery included various techniques for gross primary
tumor removal with flap reconstructions if technically
needed and ipsi-or bilateral neck dissection according to
the principles of head and neck cancer surgery. Indication
for postoperative radiation was seen in locally advanced
primary tumors (T3/4), positive lymph nodes (N+) or
incomplete resection. In case of incomplete resection or
positive lymph nodes with extracapsular extension, pa-
tients were scheduled for simultaneous platin-based
chemotherapy if medically fit. Surgery attempted gross
complete removal of the primary by various techniques
and ipsi-or bilateral neck dissection. Radiation was
planned to be initiated 4–8 weeks after surgery if primary
wound closure was achieved.
Radiation therapy
All patients received postoperative IMRT using the step
and shoot approach. The technique used in our institution
has been described previously [14, 17, 18]. Briefly, all
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Table 1 Patient and Treatment characteristics
n % n %
Age Follow-up
median 58 yrs median 55 mo
min 35 yrs min 5 mo
max 85 yrs max 150 mo
Gender RT break > 3d
male 63 84 yes 3 4
female 12 16 no 72 96
Localisation SIB
oral cavity 18 24 yes 63 84
oropharynx 57 76 no 12 16
pT stage Number of beams
pT1 23 31 median 9
pT2 36 48 min 5
pT3 9 12 max 10
pT4a 7 9
TD nodal
pN stage median 54 Gy
pN0 12 16 min 50 Gy
pN1 12 16 max 60 Gy
pN2a 5 7
pN2b 39 52 TD Boost
pN2c 7 9 median 66 Gy
min 60 Gy
clinical stage (UICC6) max 70.4 Gy
stage 1 3 4
stage 2 7 9 SD nodes
stage 3 13 17 median 1.8 Gy
stage 4a 52 69 min 1.8 Gy
max 2 Gy
Grading
G1 2 3 SD Boost
G2 43 57 median 2.2 Gy
G3 30 40 min 2 Gy
max 2.33 Gy
ECE
yes 22 29 Chemotherapy
no 53 71 yes 53 71
no 22 29
Perineural invasion
Pn0 70 93 CHT scheme/compl.
Pn1 5 7 Cis weekly 47 89a
Carbo/5-FU 5 9a
Number of pos. nodes Cetuximab 1 1a
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patients were fixed in an individually manufactured
precision head mask made of Scotch cast (3 M, St. Paul,
Minneapolis, MN) and a vacuum pillow for the body.
With this immobilization system attached to the stereo-
tactic base frame, contrast-enhanced CT-images were per-
formed with a slice thickness of at least 3 mm. Target
volume definition differed slightly over time but usually
the primary clinical target volume included the surgical
tumor bed with a safety margin of 1 cm and the bilateral
regional lymph nodes areas (retro-, parapharyngeal, cer-
vical nodes level Ib-V). Secondary CTVs (Boost) covered
the surgical tumor bed and the regions of involved lymph
nodes with extracapsular extension. A PTV margin of
3–5 mm was added manually to the CTVs. Margins
could be reduced in case of directly adjacent organs at
risk. Inverse treatment planning was performed using
the KonRad and VIRTOUS software developed at the
German Cancer Research center (DKFZ). EBRT was de-
livered by linear accelerators with 6 or 15 MV photons
using an integrated motorized multileaf collimator
(MLC) in step-and shoot technique. Since the introduc-
tion of a kV-CT on rails in 2002, all patients received
image guidance (with the possibility for replanning if
necessary) at least once a week. The total doses were
prescribed to the median of the target volume and usually
the 95 % isodose surrounded the PTV. A simultaneously
integrated boost concept (SIB) was used in the majority of
patients (84 %). According to this concept, the boost
volume (surgical bed, nodal regions with ECE) should be
covered with 66 Gy (single dose 2.2 Gy) while the nodal
areas should receive 54 Gy (single dose 1.8 Gy) in 30 frac-
tions. An example of a three dimensional dose distribution
including a DVH sample is shown in Fig. 1. At least one
parotid gland was spared (mean dose lower than 26 Gy). In
patients with sequential boost concepts, conventional frac-
tionation was used (1.8-2 Gy). Chemotherapy schedules
varied slightly over time, but in general patients were
scheduled for concurrent platin-based systemic therapy in
case of microscopic residual disease (R1 resection), close
margin resection or if extracapsular extension was present.
Follow-up
Regular follow-up visits took place either at our or at the
referring center. At our institution, patients were
Table 1 Patient and Treatment characteristics (Continued)
n≤ 2 44 59 >80 % of scheduled 41 77a
n > 2 31 41 <80 % of scheduled 12 23a
Resection margin Neck dissection
R0 48 64 ipsilateral 34 45
R1 27 36 bilateral 41 55
Yrs years, min minimum, max maximum, n number, %:percentage, UICC6 union international contre le cancer staging manual 6th edition, ECE extracapsular
extension, pos. positive, RT radiation therapy, d days, mo months, TD total dose, SD: single dose, CHT chemotherapy, compl.:completion, Cis cisplatin, Carbo
carboplatin, 5-FU5-fluorouracil, SIB simultaneously integrated boost, apercentage of 53 patients with CHT
Fig. 1 Example of dose distribution and DVH. Treatment plan for a patient with postoperative chemoradiation with cisplatin weekly, prescription
dose 54 Gy to nodal region (single dose 1.8 Gy) and simultaneously integrated boost with 66 Gy (single dose 2.2 Gy), left: dose distribution, right:
DVH, 2: myelon, 3: brainstem, 10/11: parotid glands, 13: nodal PTV, 14: boost PTV
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scheduled for follow up visits every 3 months for the
first 2 years, every six months for the following 3 years
and annually thereafter. Each visit included at least clin-
ical examination and CT or MRI of the head and neck.
In case of evidence for locoregional recurrence or distant
spread, additional tests or imaging modalities were
performed to confirm or exclude disease progression at
the discretion of the treating physician. Missing data were
completed by calling the patients or the treating physician.
Definition of events
Local control (LC) was defined as absence of tumor
regrowth in the region of the primary tumor. Neck
control (NC) was defined as absence of tumor regrowth
in the bilateral regional nodes. Locoregional control
(LRC) was defined as absence of local or neck recur-
rence. In patients without further assessment of LC/NC/
LRC, for example after development of distant spread,
the date of the last information about the local/neck/re-
gional status was used for calculation. Distant control
(DC) was defined as absence of distant failure. Freedom
from treatment failure (FFTF) was defined as absence of
regional or distant failure. All patients were (re-)-staged
according to UICC 6th edition. Postoperative complica-
tions, acute and late side effects were reported as docu-
mented in the patient charts. Acute toxicity was scored
according to Common Toxicity Criteria version 3.0
(CTCAE V3.0) from the start of radiation therapy until
3 months of follow up. Late toxicity was scored accord-
ing to CTCAE 3.0 thereafter until the end of follow-up.
If multiple occurence was documented, the most severe
grade of a specific event was used for grading. Disease
related functional impairments present prior to the start
of chemoradiation were scored as toxicity only if wors-
ening occurred. Xerostomia was scored as subjectively
assessed by the patients and graded according to Radi-
ation Therapy Oncology Group (RTOG)/European
Organization for Research and Treatment (EORTC)
radiation morbidity scoring criteria [19].
Statistical and ethical considerations
Time to event data was calculated from the first day of
radiation treatment until the last follow up information
or until death using the Kaplan-Meier method. Subgroups
were compared using the log-rank test. Parameters with
p < 0.1 in univariate analysis were entered into a Cox
regression model for multivariate analysis. Differences
were considered statistically significant for a p-value
of ≤ 0.05. The study is in compliance with the Declar-
ation of Helsinki (Sixth Revision, 2008). Furthermore
the study was approved by the Independent Ethics
Committee of the Medical Faculty Heidelberg (Ref. Nr.:
S-170/2012). All patients gave written informed consent
before treatment initiation.
Results
The median follow up for the entire cohort was 55 months
(5–150) and 62 months in survivors (12–150). Only two
of the surviving patients had a follow-up interval less than
2 years. Radiation Treatment breaks >3 days were needed
in 3 patients (one due to skin/mucosal toxicity, one due to
suspected flap necrosis and one due to acute appendicitis).
Median radiation treatment time was 43 days (36–57
days). 77 % of the patients scheduled for chemotherapy
received at least 80 % of the planned chemotherapy dose.
Locoregional control
We observed a total of 13 locoregional failures (4 isolated
local, 4 isolated neck and 5 combined), transferring into
estimated 3-and 5-year locoregional control rates of 85 %
(Fig. 2). The corresponding 3-and 5-year figures for local
control and neck control were 90 % and 89 %. The num-
ber of positive lymph nodes (n > 2) and the presence of
ECE were significantly associated with decreased locore-
gional and neck control in univariate analysis (Table 2,
Fig. 3), but only the number of positive nodes remained
significant according to multivariate analysis. Regarding
local control, also postoperative T stage and presence of
perineural invasion were significantly affected with worse
outcome but only T stage remained significant in multi-
variate analysis (data not shown).
Distant control, FFTF and OS
Distant metastases were observed in 11 patients mainly to
the lung (n = 8), transferring into estimated 3-and 5-year
distant control rates of 85 % (Fig. 2). Higher postoperative
T stage (pT3/4), higher N stage (pN2) and number of
positive nodes (n > 2) significantly affected distant control
in univariate analysis (Table 2, Fig. 3). Overall treatment
failure occurred in 20 patients (9 locoregional only, 7 dis-
tant only, 4 combined), transferring into estimated 3-and
5-year FFTF rates of 77 % and 75 %, respectively (Fig. 2).
The estimated 3-and 5-year overall survival rates were
80 % and 72 %, respectively (Fig. 2). Worse FFTF and OS
were significantly associated with postoperative N2 stage,
clinical stage 4, number of positive nodes (n > 2), presence
of ECE and perineural invasion (Table 2, Fig. 3). According
to multivariate analysis, only the number of positive nodes
was significantly associated with worse FFTF while none of
the factors remained significant regarding overall survival.
Toxicity
Postoperative complications were documented in 23
patients (31 %), mainly as persistent dysphagia or aspir-
ation requiring percutaneous endoscopic gastrostomy
tubes (PEG, n = 13, 17 %), see Table 3. Surgical revisions
were needed in 5 patients (7 %). Maximum acute toxicity
grade 3 was scored in 48 patients (64 %) mainly as
leukopenia or mucositis/dysphagia and grade 4 in one
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patient (leucopenia), see Table 4. This includes 25
patients scored as grade 3 dysphagia due to presence of
a PEG at the initiation of radiation therapy (13 with
PEGs placed due persistent dysphagia or aspiration post-
operatively, 12 with PEGs placed prophylactically at the
discretion of the treating physician), resulting in a over-
all acute grade 3 dysphagia rate of 52 %. If only the 50
patients without PEG at the initiation of radiation ther-
apy were regarded, the rate of grade 3 dysphagia would
have dropped to 28 %, see Table 5. Maximum late
toxicity grade 3 was documented in 17 patients (23 %),
mainly as long term PEG dependency (n = 11, 15 %), see
Table 6. Patients with PEGs due to postoperative com-
plications had a markedly increased risk of long-term
tube dependency (5/13, 38 %) compared to patients who
received PEGs for other reasons or not at all during
radiation therapy (6/62, 10 %), see Table 5.
Discussion
In our current analysis of 75 patients suffering from oral
cavity or oropharyngeal squamous cell carcinoma, we
show that encouraging locoregional control rates (5-year
LRC 85 %) and overall survival rates (5-year OS 72 %)
can be achieved with postoperative IMRT with or with-
out simultaneously applied chemotherapy according to
the presence of established risk factors with acceptable
acute and limited late toxicities. Despite the general
limitations in comparing different studies, our results
seem to compare favourable with the findings of large
prospective trials using similar approaches with conven-
tional radiation techniques in head and neck cancer espe-
cially with regard to overall survival [3, 4]. For example,
Bernier et al. [4] reported a 5-year local or regional recur-
rence rate of 18 % and a 5-year overall survival rate of
53 % in the chemoradiation arm of EORTC 22931 using a
slightly different dose concept combined with cisplatin.
Cooper et al. [3] described a 10-year local or regional
recurrence rate of 22 % and an estimated 5-year overall
survival of 46 % in the chemoradiation arm of RTOG
9501 which was similarly designed to EORTC 22931.
Although the majority of patients in these studies suffered
from oral cavity or oropharyngeal cancers (56-72 %),
hypopharyngeal and laryngeal cancers were also included
which might have affected the overall results. Further on,
the use of IMRT in the present study instead of conven-
tional radiation might have led to an improved overall
survival due to decreased late toxicities, but given the
retrospective nature and the small sample size of our
study, it cannot be ruled out that these differences
occurred simply by selection bias or randomly. However,
our results are also in good accordance with other studies
focusing on IMRT and/or oral cavity and oropharyngeal
cancer using modern radiation techniques. For example,
Chen et al. [20] analyzed 90 consecutive head and neck
Fig. 2 Outcome of the entire cohort. FFTF: freedom from treatment failure
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Table 2 Univariate analysis of prognostic factors
LRC DC FFTF OS
5-yr rate p value 5-yr rate p value 5-yr rate p value 5-yr rate p value
Age
<58 yrs 81 % 0,144 80 % 0,803 71 % 0,349 71 % 0,932
≥58 yrs 89 % 86 % 79 % 72 %
Gender
male 86 % 0,598 81 % 0,439 73 % 0,745 70 % 0,503
female 83 % 91 % 83 % 81 %
Localisation
oral cavity 78 % 0,623 80 % 0,246 72 % 0,956 77 % 0,503
oropharynx 87 % 92 % 76 % 70 %
Grading
G1 100 % 0,781 100 % 0,48 100 % 0,485 100 % 0,21
G2 84 % 86 % 76 % 77 %
G3 87 % 77 % 72 % 62 %
pT stage
pT1/2 88 % 0,169 87 % 0,035 78 % 0,155 75 % 0,374
pT3/4 74 % 66 % 63 % 59 %
pN stage
pN0/1 96 % 0,167 96 % 0,05 96 % 0,017 88 % 0,006
pN2 80 % 76 % 65 % 63 %
clinical stage (UICC6th)
stage 1/2/3 96 % 0,194 95 % 0,06 96 % 0,023 88 % 0,009
stage 4a 81 % 76 % 64 % 64 %
Neck dissection
ipsilateral 91 % 0,318 90 % 0,13 81 % 0,311 85 % 0,082
bilateral 80 % 76 % 69 % 59 %
Number of pos. nodes
≤2 98 % 0,001 93 % 0,005 93 % 0,001 84 % 0,001
>2 67 % 65 % 49 % 53 %
Perineural invasion
no 87 % 0,092 83 % 0,452 77 % 0,016 74 % 0,044
yes 60 % 80 % 40 % 30 %
Resection margin
R0 81 % 0,725 86 % 0,609 75 % 0,745 67 % 0,499
R1 93 % 78 % 75 % 80 %
ECE
no 94 % 0,002 85 % 0,309 85 % 0,005 79 % 0,003
yes 64 % 73 % 52 % 53 %
CHT
yes 83 % 0,373 79 % 0,335 70 % 0,179 69 % 0,134
no 90 % 90 % 86 % 80 %
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cancer patients treated with surgery, postoperative IMRT
+/−chemotherapy and found a 2-year locoregional control
rate of 80 % and a 2-year overall survival rate of 79 %.
Collan et al. [5] reported a cohort of 102 patients with a
stage distribution similar to ours treated by postoperative
IMRT up to a median dose of 60 Gy with 38 % of them
receiving simultaneous chemotherapy. With a median
follow up of 55 months, they observed very high 5-year
LRC and OS rates of ~90 % (estimated from printed
curve) and 84 %, respectively. Wang et al. [11] analyzed 88
patients with primaries located in oral cavity or orophar-
ynx of whom 44 received postoperative IMRT up to 66 Gy
(SD 2.2 Gy) mainly without chemotherapy with a slightly
more favourable stage distribution. After a median follow-
up of 53 months, they found estimated 4-year LRC control
and OS rates of 84 % and 71 %, respectively. In summary,
postoperative IMRT with/without chemotherapy seems to
result in encouraging LRC and OS rates in patients with
oral cavity or oropharyngeal cancers based on our results
and the limited available literature.
Prognostic factors
Despite the relatively small sample size, we used univariate
and multivariate analyses to investigate possible prognos-
tic factors specifically for oral cavity and oropharyngeal
cancer cases. Regarding locoregional control, we found
that presence of ECE and number of positive nodes (n > 2)
were associated with worse outcome in univariate analysis,
but only the number of positive nodes remained signifi-
cant according to multivariate Cox regression. Regarding
FFTF and OS, worse outcome was associated with N2
stage, clinical stage 4 disease, number of positives nodes,
presence of ECE and perineural invasion in univariate
analysis, but again only the number of positive nodes
remained significant according to multivariate analysis at
least for FFTF. These findings were surprising at least to
Table 2 Univariate analysis of prognostic factors (Continued)
Lymph node >3 cm
yes 94 % 0,176 89 % 0,566 84 % 0,319 77 % 0,751
no 82 % 80 % 72 % 69 %
LRC locoregional control, DC distant control, FFTF freedom from treatment failure, OS overall survival, yr: year, yrs years, UICC6th union international contre le
cancer staging manual 6th edition. pos. positive, ECE extracapsular extension, CHT: chemotherapy, cm centimetre, %:percentage, bold: significant p-values
Fig. 3 Outcome according to number of positive lymph nodes (n≤ 2 vs >2). LRC: locoregional control, DC: distant control, FFTF: freedom from treatment
failure, OS: overall survival
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some extent as microscopic incomplete resection and
presence of ECE have been reported as strongest factors
influencing locoregional control and overall survival
according to major prospective trials [3, 4, 6], while the
number of positive nodes is a less established factor. For
example, the combined analysis of EORTC 22931 and
RTOG 9501 (which stratified patients according to slighty
different risk factors) observed a significant benefit for
adding chemotherapy to postoperative radiation only for
the common factors (positive margin and ECE), while the
presence of risk factors which have been used for risk
assessment only in one of the trials (number of positive
nodes ≥2, level 4/5 involvement, vascular embolisms, peri-
neural disease, stage III/IV) had a weaker or no prognostic
Table 3 postoperative complications
postoperative complications number percent
local
dysphagia requiring feeding tube 13 17
bleeding 4 5
wound healing disturbance/flap necrosis 3 4




pulmonary embolism 1 1
tachyarrhythmia 1 1
hypertensive crisis 1 1
pseudomembraneous colitis 1 1
pneumonia 1 1
delirium 1 1
surgical revisions 5 7
n number, %: percentage, MI myocardial infarction, DVT deep vein thrombosis,
some patients had more than one postoperative complication
Table 4 Acute toxicities
acute toxicities all grades grade 3/4a
n % n %
non-hematological
dysphagiab 68 91 39 52
mucositis/stomatitis 61 81 8 11
weight loss 32 43 5 7
skin 64 85 3 4
nausea/vomitting 29 39 3 4
horseness/larynx edema 9 12 1 1
hearing loss 9 12 1 1
renal injury 7 9
dry eye 1 1
hand foot syndrome 1 1
other 3 4 2 3
hematological
leucoytopenia 39 52 8 10
infection 16 21 5 7
anemia 51 68 4 5
thrombocytopenia 18 24
a: only one patient had a grade 4 toxicity (leucopenia), ball patients included
with PEGs regardless of its reason or use, some patients had more than one
acute toxicity
Table 5 Acute and late dysphagia in relation to PEG placement
Dysphagia all patientsa without PEG at start of RT
n % (n = 75) n % (n = 50)
grade 0 7 9 7 14
grade 1 22 29 22 44
grade 2 7 9 7 14
grade 3 39 52 14 28
PEG prior or during RT long term after RT
n % n %
postoperativeb 13 17 5 38
prophylacticc 12 16 2 17
symptomaticd 7 9 0 0
nonee 43 57 4f 9
PEG percutaneous endoscopic gastrostomy tube, RT radiation therapy, a: all
patients with PEG during RT regardless of reason for placement or use scored
as grade 3 dysphagia, b: patients who received PEG postoperatively due to
aspiration or persistent dysphagia until initiation of RT, c: patient who received
PEG for prophylactic reasons prior to initiation of RT on discretion of the
treating radiation oncologist, d: patients who received PEG during RT due to
dysphagia, e: patients who did not receive a PEG during the whole course of
RT, fpatients who needed PEG due to development of late dysphagia after
completion of the full RT course
Table 6 Late toxicities
late toxicities all grades grade 3
n % n %
dysphagia 28 37 11 15
hearing loss 9 12 3 4
xerostomia 38 51 2 3
hoarseness/laryngeal edema 7 9 2 3
abcess/fistula 2 3 2 3
trismus 8 11 1 1
osteonecrosis 1 1 1 1
taste alterationa 16 21
lymph edema 8 11
mucosal damage 4 5
hypothyreosis 3 4
dental damage 2 3
skin damage 1 1
esophageal stenosis 1 1
aonly grade 1 and 2 possible according to CTCAE3.0, some patients had more
than one late toxicity
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value at all [6]. However, our patients received chemother-
apy based on the presence of the established risk factors
close/positive margins or ECE, thus it cannot be ruled out
that the addition of chemotherapy improved the results in
those patients to a level comparable to patients at lower
risk receiving postoperative RT alone and therefore mim-
icked their prognostic relevance with regard to the entire
cohort. In contrast, the number of positive nodes did not
trigger the use of additional chemotherapy, possibly main-
taining its influence as highlighted by several reports sup-
porting the significance of the number of positive nodes
or the lymph node ratio as prognostic factors in head and
neck cancer [21, 22]. For example Hua et al. [21] de-
scribed a highly significant association between number of
positive nodes (threshold ≤ 3 vs > 3) and lymph node ratio
with the median overall survival in 81 patients suffering
from hypopharyngeal cancer treated by surgery only. Wan
et al. [22] evaluated 1510 patients with head and neck
cancer treated by surgery alone, adjuvant radiation or
adjuvant chemoradiation and found a strong and signifi-
cant association between the number of positive nodes
and locoregional control, disease specific survival and
overall survival. In a subset analysis, they further described
no significant difference in DSS or OS between patients
with one or two positive nodes but significant worsening
if three or more nodes were involved. Similarly, we found
that the number of positive nodes was the only factor
which significantly influenced all oncological endpoints in
univariate analysis and the only factor which influenced
LRC and FFTF in multivariate analysis. Interestingly the
strongest discrimination in our cohort was found for the
same threshold (≤2 vs > 2) as in the study by Wan et al.
[22]. We performed a separate analysis using the threshold
introduced by Cooper et al. (<2 vs ≥ 2) [3], which provided
similar results in univariate and multivariate analysis with
regard to significance but with weaker discrimination
(data not shown). Given the different thresholds reported
in the mentioned studies with similar results, it seems at
least reasonable to assume, that locoregional control and
overall survival will worsen with an increasing number of
positive nodes irrespective of arbitrarily set distinctions.
Toxicity
We observed maximum acute grade 3 toxicities in about
two thirds of our patients, mainly hematological and
mucositis/dysphagia. These findings are in line with the
reports of other studies investigating postoperative radio
(chemo) therapy in head and neck cancer. For example
Cooper et al. [3] found maximum acute grade 3/4 toxic-
ities in 34 % of the patients treated by postoperative
radiation alone and 77 % if chemoradiation was used.
Geretschläger et al. [23] described 66 % acute grade 3 side
effects in their cohort of patients with oral cavity
cancer treated by postoperative IMRT. Regarding only
hematological side effects, 30 % grade 3 and 8 %
grade 4 hematological toxicities were found in the
chemoradiation arm of RTOG 9501 [3] and 16 %
severe leucopenia was reported in the chemoradiation
arm of the EORTC 22931 study [4], indicating that
those toxicities are mainly driven by the (similar)
chemotherapy component and not influenced by radi-
ation technique or disease site relevantly.
The combined rate of severe acute mucositis/dysphagia
was also similar with roughly 60 % in our study compared
to 66 % in the chemoradiation arm of RTOG 9501 [3] and
51 % in the EORTC 22931 study [4], however we found a
different distribution. While in those trials more patients
had severe mucositis than dysphagia, we observed an op-
posite ratio. This might be due to the fact that our analysis
was limited to oral cavity and oropharyngeal cancer result-
ing in the inclusion of swallowing structures into the high
dose boost areas in most patients, however it seems also
linked to the definition and grading of dysphagia. In our
analysis, all patients who had a feeding tube at any time
during radiotherapy were scored at least as grade 3
dysphagia, although many of them received their PEGs
already due to postoperative complications or prophylac-
tically prior to RT. If only those patients were considered
without PEGs at the beginning of RT, the severe dysphagia
rate would have dropped to 28 %, similarly to the 25 % in
the chemoradiation arm of RTOG 9501 [3]. Interestingly,
we found a clearly increased risk of long-term PEG
dependency in patients who had PEG placement due to
postoperative complications compared to placement for
other reasons or not at all. The use of feeding tubes for
nutritional support is a common but heavily discussed
issue in head and neck radiation therapy. It has been
estimated that 50-70 % of patients require a feeding tube
during definitive chemoradiation, 15-40 % with definitive
RT and 20-40 % with surgery followed by adjuvant RT [24].
Many investigators favor the prophylactic use of feeding
tubes because of numerous reports describing less weight
loss, improved 6-month quality of life, less morbidity and
fewer hospitalizations including one randomized trial
supporting this approach [25–27]. However, an increasing
number of reports described high percentages of unneces-
sary (unused) prophylactic feeding tube placements of up
to 50 % [28], a higher likelihood of prolonged or perman-
ent dependency [29] and an increased rate of esophageal
strictures [30], thus favoring a more reactive approach.
Unfortunately most reports focused on patients with
definitive radio (chemo) therapy resulting in very limited
data for patients treated with postoperative radiation [31].
Collan et al. [5] described 5 % patients with long term PEG
dependency but did not report details about reasons for
placement. Bastos de Souza et al. [9] found 8 % long term
dependency in a cohort of 256 patients treated by surgery
alone or surgery plus radiotherapy. We did not observe a
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major difference in prolonged PEG dependency between
patients with prophylactic (17 %), symptomatic (0 %) or no
placement (9 %) during radiotherapy and therefore are not
able to add evidence to this issue, however we found that
patients with postoperative swallowing complications
requiring tube feeding are at increased risk (39 %) for
prolonged PEG-dependency after postoperative radio
(chemo) therapy and should be counseled accordingly.
Consistent with prior results published by our group
[14, 32, 33] and several other studies [12, 13] who found
decreased rates of severe xerostomia with IMRT in head
and neck cancer in general or in distinct subgroups, we
observed a low rate (3 %) of severe xerostomia with
postoperative IMRT also in the treatment of oral cavity
and oropharyngeal cancers. For example Collan et al. [5],
who focused similarly on the postoperative treatment of
oral cavity and oropharyngeal cancers even observed no
grade 3 xerostomia with IMRT at all. Wang et al. [11]
compared IMRT with conventional RT in a similar
subgroup and described a significant reduction of severe
xerostomia in favour of IMRT (0 vs 35 %). Two random-
ized prospective trials have recently highlighted the value
of IMRT [12, 13] by showing a significant reduction of late
xerostomia compared to conventional or 3D-conformal
RT in head and neck cancer in general, confirming a
plethora of clinical and dosimetric studies with similar
findings.
In contrast to other reports focusing on postoperative
IMRT in oropharyngeal/oral cavity cancer most of our
patients were treated with a simultaneously integrated
boost (SIB) concept using slightly increased single
doses (up to 2.2 Gy) in the boost area. SIB techniques
allow a slightly reduced overall treatment time and
result in increased dose conformity regarding the boost
area but have been associated with concerns regarding
additional toxicity. Although inter-study comparisons
are generally difficult and possibly flawed with several
biases including patient selection or the use of different
scoring systems, we did not observe markedly increased
rates of acute or late toxicities compared to reports on
sequential IMRT boost techniques [5, 23]. This is espe-
cially true for damage to mucosal or swallowing struc-
tures, which are regarded as possibly associated with
increased single doses. However, our acute grade 3
toxicity rates of 11 % for mucositis and 28 % for
dysphagia (in patients without prophylactic PEG
placement) were at least comparable to Collan et al.
(mucositis grade 3: 25 %) [5] and Geretschläger et al.
(mucositis grade 3: 36 %, dysphagia grade 3: 34 %) [23]
using strictly sequential boosts. Regarding late dyspha-
gia, our rate of 15 % was slightly increased compared to
5-9 % in the mentioned reports [5, 23], however Collan
et al. [5] treated their patients with a considerably
lower median total dose compared to our study and
Geretschläger et al. [23] included only patients with
oral cavity tumors probably resulting in lower doses to
the swallowing structures. Gupta et al. [12] recently
used an integrated boost concept very similar to ours
in a prospective phase randomized trial and reported
very low rates of grade 3 mucositis (6 %) and dysphagia
(10 %). Finally, Spiotto et al. compared IMRT using
sequential and integrated boost concepts in advanced
head and neck cancers and reported significantly
reduced acute grade 3 mucositis for the integrated
boost group [34]. In summary, the use of an integrated
boost technique with slightly increased single doses
does not seem to result in markedly increased toxicities
compared to sequential boosting techniques.
Obviously our study has some limitations, mainly its
retrospective nature and its limited number of patients.
Nevertheless, it describes a homogenous cohort of con-
secutive patients with oral cavity or oropharyngeal cancer
treated uniformly with postoperative IMRT with or with-
out chemotherapy. Thus the data may add valuable
information to the limited body of evidence specifically
addressing this subgroup of patients.
Conclusion
In summary, postoperative IMRT with or without
chemotherapy achieves excellent locoregional control
and good overall survival with acceptable acute and low
late toxicity rates. Patients who needed PEG placement
due to postoperative complications were at higher risk
for prolonged PEG dependency than patients with
prophylactic, symptomatic or no PEG placement during
radiotherapy. While the selective addition of chemother-
apy may have compensated the influence of established
risk factors like positive margins or extracapsular ex-
tension, the number of positive lymph nodes (n > 2)
remained a strong prognostic factor for all endpoints
including locoregional control and freedom from treat-
ment failure.
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